49 results
8-K
EX-99.1
CRVO
CervoMed Inc
15 May 24
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
5:06pm
to approximately $1.4 million for the same period in 2023.
Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2024 were approximately
8-K
EX-99.1
CRVO
CervoMed Inc
5 Apr 24
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
4:06pm
million for the year ended December 31, 2023, compared to no revenue for the same period in 2022.
Research and Development (R&D) Expenses: R&D expenses
8-K
EX-99.1
43oaob3hs9yr lq
13 Nov 23
CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights
4:06pm
8-K/A
EX-99.1
l4ml2irtveo3rtsj
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K/A
EX-99.3
6xxm5v
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
424B3
nb5mid49d
13 Jul 23
Prospectus supplement
4:32pm
S-4/A
uorkd6iql435miq97wme
22 Jun 23
Registration of securities issued in business combination transactions (amended)
9:46pm
S-4
pw8s rokp
10 May 23
Registration of securities issued in business combination transactions
9:56pm
425
EX-2.1
wz1fjxwgog251
30 Mar 23
Business combination disclosure
8:51am
8-K
EX-2.1
45ckeluy86yn
30 Mar 23
Form of Parent Stockholder Support Agreement
8:50am
DEFC14A
6hn4g6h8 kx8
5 Dec 22
Proxy in contested solicitation
5:12pm
PRER14A
ujlwdoyypv
28 Nov 22
Preliminary revised proxy
5:17pm